Pages that link to "Q80024902"
Jump to navigation
Jump to search
The following pages link to Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia (Q80024902):
Displaying 50 items.
- Management of antipsychotic-related weight gain (Q24610124) (← links)
- Osteoprotegerin levels in patients with severe mental disorders (Q24626094) (← links)
- Schizophrenia: a multisystem disease? (Q24633845) (← links)
- Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity (Q26752342) (← links)
- Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis (Q26770197) (← links)
- Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients (Q27027832) (← links)
- From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism (Q28067617) (← links)
- The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis (Q28545094) (← links)
- Molecular substrates of schizophrenia: homeostatic signaling to connectivity (Q30383611) (← links)
- Identification of targeted analyte clusters for studies of schizophrenia (Q30476776) (← links)
- Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients (Q33453744) (← links)
- Association of the PPAR-γ Gene with Altered Glucose Levels and Psychosis Profile in Schizophrenia Patients Exposed to Antipsychotics. (Q33620389) (← links)
- Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders (Q33703032) (← links)
- The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia (Q33968686) (← links)
- S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance (Q33984573) (← links)
- Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse (Q34018212) (← links)
- Modulation ofTcf7l2 expression alters behavior in mice (Q34064796) (← links)
- Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? (Q34183495) (← links)
- A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism (Q34183522) (← links)
- A positive association between homeostasis model assessment of insulin resistance score and the Trp64Arg polymorphism of the β3-Adrenergic receptor gene in schizophrenia patients in Taiwan (Q34318126) (← links)
- The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis (Q34542274) (← links)
- Cardiovascular risk in a first-episode psychosis sample: A ‘critical period’ for prevention? (Q34634393) (← links)
- Levels of S100B are raised in female patients with schizophrenia. (Q34738782) (← links)
- Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. (Q35075344) (← links)
- Schizophrenia: a systemic disorder (Q35323907) (← links)
- Metabolic effects of olanzapine in patients with newly diagnosed psychosis (Q35323981) (← links)
- Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls (Q35537155) (← links)
- Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? (Q35768175) (← links)
- Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia (Q35907531) (← links)
- Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia (Q36310008) (← links)
- Recommendations on screening for type 2 diabetes in adults (Q36338862) (← links)
- Beyond the brain: disrupted in schizophrenia 1 regulates pancreatic β-cell function via glycogen synthase kinase-3β. (Q36466996) (← links)
- Potential metabolite markers of schizophrenia. (Q36479055) (← links)
- Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. (Q36593819) (← links)
- Diabetes or prediabetes in newly diagnosed patients with nonaffective psychosis? A historical and contemporary view (Q36621014) (← links)
- Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis (Q36621075) (← links)
- Adult medication-free schizophrenic patients exhibit long-chain omega-3 Fatty Acid deficiency: implications for cardiovascular disease risk (Q36692065) (← links)
- Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives (Q36784390) (← links)
- Abnormal glycemic homeostasis at the onset of serious mental illnesses: A common pathway (Q36835108) (← links)
- The proteome of schizophrenia (Q36848272) (← links)
- Proteomic profiling in schizophrenia: enabling stratification for more effective treatment (Q36998471) (← links)
- Is schizophrenia a syndrome of accelerated aging? (Q37044422) (← links)
- Exercise Program Adherence Using a 5-Kilometer (5K) Event as an Achievable Goal in People With Schizophrenia (Q37091453) (← links)
- Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients (Q37102229) (← links)
- Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. (Q37137023) (← links)
- Schizophrenia as a systemic disease (Q37137037) (← links)
- Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway (Q37139258) (← links)
- Glucose abnormalities in the siblings of people with schizophrenia (Q37151239) (← links)
- Differences in glucose tolerance between deficit and nondeficit schizophrenia (Q37151244) (← links)
- A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls (Q37236162) (← links)